Veterinary Medicine Information website

Tramcoat 80 mg film-coated tablets for dogs

Authorised
  • Tramadol hydrochloride
Download as PDF

Product identification

Medicine name:
Tramcoat 80 mg film-coated tablets for dogs
Active substance:
  • Tramadol hydrochloride
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Tramadol hydrochloride
    80.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Film-coated tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
      • All relevant tissues
        no withdrawal period
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QN02AX02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Belgium
Package description:
  • Cardboard box of 1 PVC/PE/PVDC-aluminium blister, containing 10 tablets.
  • Cardboard box of 2 PVC/PE/PVDC-aluminium blister, containing 10 tablets.
  • Cardboard box of 3 PVC/PE/PVDC-aluminium blister, containing 10 tablets.
  • Cardboard box of 4 PVC/PE/PVDC-aluminium blister, containing 10 tablets.
  • Cardboard box of 5 PVC/PE/PVDC-aluminium blister, containing 10 tablets.
  • Cardboard box of 6 PVC/PE/PVDC-aluminium blister, containing 10 tablets.
  • Cardboard box of 7 PVC/PE/PVDC-aluminium blister, containing 10 tablets.
  • Cardboard box of 8 PVC/PE/PVDC-aluminium blister, containing 10 tablets.
  • Cardboard box of 9 PVC/PE/PVDC-aluminium blister, containing 10 tablets.
  • Cardboard box of 10 PVC/PE/PVDC-aluminium blister, containing 10 tablets.
  • Cardboard box of 12 PVC/PE/PVDC-aluminium blister, containing 10 tablets.
  • Cardboard box of 25 PVC/PE/PVDC-aluminium blister, containing 10 tablets.

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Hybrid application – change in strength (Article 19(1)(a) of Regulation (EU) 2019/6)
Marketing authorisation holder:
  • Alfasan Nederland B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Lelypharma B.V.
Responsible authority:
  • Federal Agency For Medicines And Health Products
Authorisation number:
  • BE-V662982
Date of authorisation status change:
Reference member state:
  • Netherlands
Procedure number:
  • NL/V/0387/004
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 18/08/2025
Download
German (PDF)
Published on: 18/08/2025
Download
French (PDF)
Published on: 18/08/2025
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 18/08/2025
Download
German (PDF)
Published on: 18/08/2025
Download
French (PDF)
Published on: 18/08/2025
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 18/08/2025
Download
German (PDF)
Published on: 18/08/2025
Download
French (PDF)
Published on: 18/08/2025
Download

Combined File of all Documents

English (PDF)
Published on: 4/04/2024
Updated on: 13/03/2026
Download
English (PDF)
Published on: 14/03/2026
Download